Karyopharm Therapeutics INC (KPTI) has disclosed a new risk, in the Accounting & Financial Operations category.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Karyopharm Therapeutics Inc. is facing significant financial challenges that cast doubt on its ability to sustain operations as a going concern. The company has reported an accumulated deficit of $1.6 billion and requires substantial funding to advance its research and development programs, particularly for the drug selinexor. Despite holding $108.7 million in cash and investments as of December 31, 2024, Karyopharm anticipates ongoing operating losses and is dependent on securing additional financing. Failure to obtain such funding could result in drastic measures, including scaling back or eliminating research projects, which would adversely affect their business operations and financial health.
Overall, Wall Street has a Strong Buy consensus rating on KPTI stock based on 4 Buys.
To learn more about Karyopharm Therapeutics INC’s risk factors, click here.
